Jordi Reverter posted this:
Licensing Manager at Institut Català de Nanociència i Nanotecnologia
Krasen Dimitrov posted this:
CEO at MAMEL&Ecobiotechnoservice
Universidad de Alcalá-OTRI posted this:Carbosilane dendrimers and their use as antiviralsThe research group in "Dendrimers for Biomedical Applications" of the University of Alcalá presents these highly branched macromolecules synthesized from a polyfunctional nucleus, of carbosilane structure and functionalized in its periphery with anionic groups that give the macromolecule a negative net charge. In addition, the invention relates to the use of the dendrimers as an antimicrobial and the process for obtaining them. The group seeks to reach collaboration agreements, licensing or commercial agreements with technical assistance, with companies in the biotechnology, pharmaceutical and biomedicine sectors in general.
Research InstituteView Profile
Germans Trias i Pujol Health Sciences Research Institute posted this:Drug Delivery PlatformColonoscopic procedures have become widespread in recent years since colorectal cancer (CRC) and inflammatory bowel disease (IBD) have become prevalent disorders. Their use has expanded as diagnostic and therapeutic tools in both elective and emergency situations. Colorectal cancer (CRC) is the most common cancer in both men and women. In the case of polypectomy, as in the case of surgery, the stabilization of the primary tumors could allow the use of optimizing chemotherapy and therefore an overall improvement in the treatment of the disease.
Universidad de Alcalá-OTRI posted this:Antimicrobial electrospun fiber membrane with retention and controlled release capacity of active substancesResearchers from the Department of Analytical Chemistry, Physical Chemistry and Chemical Engineering of the University of Alcalá in collaboration with researchers from the Department of Chemistry and Physics of the University of Almería, presents a procedure for the manufacture of active membranes based on submicron fibers combining an antimicrobial action with the ability to retain apolar contaminants in aqueous solution. The membranes are produced by an electrospinning process in aqueous solution from mixtures of water soluble polyacids and polyols, which are subsequently stabilized by a thermal curing process and post-functionalized by the incorporation of amino-terminated dendrimers by a grafting process using a coupling agent. The material can be applied to the treatment of drinking water, to the regeneration of waste water, to the treatment of process waters and also to the controlled release of active substances, such as drugs, food preservatives, etc. The group seeks companies from the pharmaceutical, food, material technology and environmental sectors to sign technical cooperation agreements, commercial agreement with technical assistance and patent licensing agreements.
Universidad de Alcalá-OTRI posted this:Carbosilane dendritic compounds homo and heterofunctionalizedA Spanish research group from the Department of Organic and Inorganic Chemistry of Alcala University has developed a highly branched macromolecules called dendrimers or dendrons, with carbosilane structure and functionalized on its periphery with anionic or cationic groups, providing the macromolecule a net negative or positive charge respectively. The invention also concerns the dendrimers’ procurement process and their biomedical applications, particularly as carriers of drugs or nucleic acids (such ODN, siRNA, dsRNA or DNA), or as therapeutic agents with antiviral or antibacterial activity. The group is looking for companies in the biomedical sector to reach licensing agreements, collaboration and commercial agreements with technical assistance.
Universidad de Alicante posted this:Multicapillary nebulizer for simultaneous nebulization of two or more liquids A Spanish university research group has developed a new pneumatic multicapillary nebulizer which allows the simultaneous nebulization of two or more liquids, miscible or immiscible between them. This device offers the possibility of simplifying the analysis process, reducing the consumption of resources and a high mixing efficiency is achieved. A laboratory-constructed prototype is available for any demonstration. The research group is looking for companies interested in license agreement.
Centre Technology Transfer CITTRU posted this:Polymer material based on modified polysaccharides for heparin removal and neutralisation in medical applications (removal of heparin from blood and body fluids)Heparin has many clinical applications due to potent activity for inhibition of blood clotting. Heparin is a drug of choice when quick anticoagulant effect is required, e.g. during surgical procedures, and especially to prevent clotting of blood in devices for extracorporeal therapy, like dialysers and cardiopulmonary bypasses. The use of heparin carries a risk of serious side-effects, among of which bleedings, thrombocytopenia and osteoporosis are most frequent. Due to the side-effects heparin should be removed from the bloodstream as soon as the anticoagulant effect is no longer needed. The most common method is administration of protamine, a small protein that is a heparin antagonist. Another polymer used to inactivate heparin is poly-L-lysine, also applied to enhance the effect of protamine. Moreover, heparin can be neutralised by enzymatic degradation with immobilised heparinase. However, the current methods of heparin removal themselves can produce side-effects. For example, as many as 10% of patients suffer from unwanted reactions caused by protamine that can have severe consequences, including fatal events. Among the side-effects there are: pulmonary hypertension, arterial hypertension, anaphylactic crisis, thrombocytopenia, granulocytopenia, complement activation and release of cytokines. Furthermore, protamine-induced heparin neutralisation is incomplete and followed by allergic reaction. Poly-L-lysine, on the other hand, is a relatively expensive polymer.
IDIBELL posted this:Companion diagnostic for cutaneous and uveal melanomaCompanion diagnostic for cutaneous and uveal melanoma. Our combination drug therapy for metastatic melanoma offers an alternative treatment for patients that do not have the BRAF V600 mutation or for patients resistant to Vemurafenib. Additionally, our technology can be used as a prognostic test to predict the risk of metastasis in uveal and cutaneous melanoma.